Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Insulin prices

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Sanofi reception

Sanofi plans 18 new product launches by 2020

Keen to reinstall faith of investors after firing CEO Viehbacher

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

Novo’s ‘virtual mannequins’ win digital award at PMEA

Med ed programme Decisions in Time was delivered with emotive

Novo taps behavioural change for diabetes programme’s re-launch

Adds health coach function to Cornerstones4Care

Eli Lilly HQ

Lilly launches GLP-1 agonist Trulicity in US

Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes

- PMLiVE

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

PMLiVE speaks to the head of clinical, medical and regulatory for Novo in the UK and Ireland

- PMLiVE

Novo Nordisk profits up 4%, buoyed by Victoza and Levemir

But expects net loss for 2014 from currency impact

- PMLiVE

Sanofi board votes out CEO Viehbacher

Unanimous decision ends weeks of speculation

- PMLiVE

US investigates Novo Nordisk manufacturing issues

Issues subpoena related to insulin plant in Kalundborg, Denmark

- PMLiVE

Regeneron top science employer, says survey

Ranked highest for third year in a row

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links